Immutep Stock Price, News & Analysis

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has provided an update on its eftilagimod alpha clinical trials, highlighting promising Phase II results in non-small cell lung cancer (NSCLC), head and neck squamous cell cancer (HNSCC), and metastatic breast cancer (MBC). The company is prioritizing 1L NSCLC for late-stage trials, with significant data expected in Q4 2022. Efti has shown strong clinical benefits especially in patients with low PD-L1 expression, suggesting a broad therapeutic potential. With approximately $80 million in cash, Immutep is funded for its expansion into early 2024.

Immutep Limited (NASDAQ: IMMP) appointed Professor Frédéric Triebel as Executive Director, enhancing its leadership team. Triebel, known for his groundbreaking work on the LAG-3 gene at Institut Gustave Roussy, has been pivotal in developing LAG-3-related therapies. His appointment aligns with Immutep’s commercialization strategy, focusing on their lead candidate, eftilagimod alpha, which shows promising clinical results and safety. With ongoing advancements and growing industry recognition, Immutep is well-positioned in the immunotherapy market.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces the expansion of its efti clinical development pipeline with a new Phase II trial targeting soft tissue sarcoma. The study, funded by a €1.5M (approx. A$2.2M) grant from the Polish government, will assess efti in combination with pembrolizumab and radiotherapy in up to 40 patients. The first patient is expected to begin dosing by H1 2023, with initial data anticipated in Q4 2024. The trial is a collaboration with the Maria Skłodowska-Curie National Research Institute of Oncology, enhancing efti's potential in cancer treatment.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the granting of a new patent by the Japanese Patent Office, enhancing its intellectual property portfolio for eftilagimod alpha (efti), a LAG-3 fusion protein. This patent protects therapeutic combinations of efti with anti-PD-(L)1 antibodies, alongside specific claims for various approved combinations. Following similar patents granted globally, this strengthens Immutep's position in the biotech sector. The patent will expire on January 8, 2036.

CEO Marc Voigt emphasized the significance of this development in conjunction with promising data from recent clinical trials.

Immutep Limited (NASDAQ: IMMP) announced promising interim results from the Phase II TACTI-002 trial for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC). Key findings include a median overall survival of 9.7 months and a 36.5% survival rate at 18 months for patients receiving efti combined with pembrolizumab. The study, which involves 36 patients, shows favorable safety and tolerability compared to traditional chemotherapy. These results support the potential of efti as a viable treatment option for advanced NSCLC patients.

Immutep Limited (NASDAQ: IMMP) announced significant progress in its clinical trials for cancer therapies. The Phase II TACTI-002 trial demonstrated a 38.6% Overall Response Rate for efti in 1st line non-small cell lung cancer patients. Additionally, biomarker analysis from the Phase IIb AIPAC trial confirmed that efti activates the immune system, correlating with improved survival rates. The company remains well-funded, with approximately $80 million in cash, ensuring operational stability into early 2024. Four notable oncologists have joined the Clinical Advisory Board to enhance strategic direction.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the grant of a new patent by the Japanese Patent Office for its pre-clinical candidate IMP761, targeting autoimmune diseases. The patent is valid until September 1, 2036, and follows a similar grant in Europe. CEO Marc Voigt highlighted the importance of protecting IMP761, which operates as a LAG-3 agonist, aiming to treat the underlying causes of autoimmune diseases. The company is collaborating with Northway Biotech for GMP compliant manufacturing ahead of clinical testing.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced new data from the Phase II TACTI-002 trial focusing on non-small cell lung cancer (NSCLC) patients. This data will be presented at the IASLC 2022 World Conference on Lung Cancer in Vienna from August 6-9, 2022. The poster's abstract will be available on July 8, 2022. The TACTI-002 trial evaluates the combination of eftilagimod alpha and pembrolizumab in patients with second line PD-1/PD-L1 refractory metastatic NSCLC. Immutep is dedicated to developing innovative immunotherapy treatments for cancer and autoimmune diseases.

Immutep has announced positive results from the Phase II TACTI-002 trial, evaluating the combination of eftilagimod alpha (efti) and pembrolizumab (KEYTRUDA) in 1^st line non-small cell lung cancer (NSCLC) patients. The study met its primary objective with an Overall Response Rate (ORR) of 38.6% across 114 patients, exceeding historical anti-PD-1 monotherapy results. Notably, responses were observed in patients with low or negative PD-L1 expression. The treatment was reported safe and well-tolerated, supporting further late-stage development.